LC is a major contributor to cancer-associated deaths worldwide, and LC with MUC16 mutation causes higher mutational burden, elevated immune checkpoint protein expression, enhanced PD-L1 amplification, and increased T-cell infiltration, all of which can be regulated with the use of PD-1 inhibitors [17, 18]. Here, MUC16 is linked to laryngotracheoesophageal cleft.